{"entity":{"id":"nct03568422","kind":"trial","name":"CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of CFI-402257 run by Canadian Cancer Trials Group, active and no longer recruiting.","summary":"CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer is a phase 1/2 interventional study registered as NCT03568422 by Canadian Cancer Trials Group, with 37 participants planned, started 2019-02-05. Conditions recorded: Breast Cancer. Interventions recorded: CFI-402257 and Paclitaxel.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03568422","url":"https://clinicaltrials.gov/study/NCT03568422"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cfi-402257"],"companies":["treadwell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03568422","phase":"1/2","setting":"A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination With Weekly Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer","sponsor":"Canadian Cancer Trials Group","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03568422/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"cfi-402257","kind":"drug","name":"CFI-402257","route":"/drugs/cfi-402257/"}],"company":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/"}]}}